Research ExplorerPublicationsSurvival advantage of Asian metastatic prostate cancer patie...

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities

Standard

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. / Würnschimmel, Christoph; Wenzel, Mike; Collà Ruvolo, Claudia; Nocera, Luigi; Tian, Zhe; Saad, Fred; Briganti, Alberto; Shariat, Shahrokh F; Mandel, Philipp; Chun, Felix K H; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre I.

In: WORLD J UROL, Vol. 39, No. 10, 10.2021, p. 3781-3787.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Würnschimmel, C, Wenzel, M, Collà Ruvolo, C, Nocera, L, Tian, Z, Saad, F, Briganti, A, Shariat, SF, Mandel, P, Chun, FKH, Tilki, D, Graefen, M & Karakiewicz, PI 2021, 'Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities', WORLD J UROL, vol. 39, no. 10, pp. 3781-3787. https://doi.org/10.1007/s00345-021-03720-7

APA

Würnschimmel, C., Wenzel, M., Collà Ruvolo, C., Nocera, L., Tian, Z., Saad, F., Briganti, A., Shariat, S. F., Mandel, P., Chun, F. K. H., Tilki, D., Graefen, M., & Karakiewicz, P. I. (2021). Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. WORLD J UROL, 39(10), 3781-3787. https://doi.org/10.1007/s00345-021-03720-7

Vancouver

Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F et al. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. WORLD J UROL. 2021 Oct;39(10):3781-3787. https://doi.org/10.1007/s00345-021-03720-7

Bibtex

@article{49f9b12d9baa41eb8af92c6c19270fad,
title = "Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities",
abstract = "PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate.METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians.RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities.CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.",
author = "Christoph W{\"u}rnschimmel and Mike Wenzel and {Coll{\`a} Ruvolo}, Claudia and Luigi Nocera and Zhe Tian and Fred Saad and Alberto Briganti and Shariat, {Shahrokh F} and Philipp Mandel and Chun, {Felix K H} and Derya Tilki and Markus Graefen and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = oct,
doi = "10.1007/s00345-021-03720-7",
language = "English",
volume = "39",
pages = "3781--3787",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities

AU - Würnschimmel, Christoph

AU - Wenzel, Mike

AU - Collà Ruvolo, Claudia

AU - Nocera, Luigi

AU - Tian, Zhe

AU - Saad, Fred

AU - Briganti, Alberto

AU - Shariat, Shahrokh F

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Tilki, Derya

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

N1 - © 2021. The Author(s).

PY - 2021/10

Y1 - 2021/10

N2 - PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate.METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians.RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities.CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.

AB - PURPOSE: To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate.METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database to identify Caucasian, African-American, Hispanic/Latino and Asian mPCa patients treated by EBRT between 2004 and 2016. Cumulative incidence plots displayed CSM after adjustment for OCM according to race/ethnicity. Propensity score matching accounted for patient age, prostate-specific antigen, clinical T and N stages, Gleason Grade Groups and M1 substages. OCM adjusted multivariable analyses tested for differences in CSM in African-Americans, Hispanic/Latinos and Asians relative to Cauacasians.RESULTS: After 3:1 propensity score matching and OCM adjustment, Asians exhibited lower CSM at 60 and 120 months (48.2 and 60.0%, respectively) compared to Caucasians (66.7 and 79.4%, respectively, p < 0.001). In OCM adjusted multivariable analyses, Asian race/ethnicity was associated with lower CSM (HR 0.66, CI 0.52-0.83, p < 0.001). Conversely, African-American and Hispanic/Latino race/ethnicity did not affect CSM. OCM rates were comparable between examined races/ethnicities.CONCLUSION: In the setting of mPCa treated with EBRT, Asians exhibit lower CSM than Caucasians, African-Americans and Hispanic/Latinos. This observation may warrant consideration in prognostic stratification schemes for newly diagnosed mPCa patients.

U2 - 10.1007/s00345-021-03720-7

DO - 10.1007/s00345-021-03720-7

M3 - SCORING: Journal article

C2 - 33978812

VL - 39

SP - 3781

EP - 3787

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 10

ER -